 |
Video: What is a Stock Split?
|
 |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. Co. discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. According to our ADVM split history records, Adverum Biotechnologies has had 1 split. | |
 |

Adverum Biotechnologies (ADVM) has 1 split in our ADVM split history database. The split for ADVM took place on March 21, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of ADVM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Adverum Biotechnologies conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ADVM split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adverum Biotechnologies shares, starting with a $10,000 purchase of ADVM, presented on a split-history-adjusted basis factoring in the complete ADVM split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/20/2015 |
|
End date: |
02/18/2025 |
|
Start price/share: |
$400.60 |
|
End price/share: |
$4.13 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.97% |
|
Average Annual Total Return: |
-36.70% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$103.16 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
03/21/2024 | 1 for 10 |
|
 |